Eupraxia Pharmaceuticals (EPRX) Total Current Liabilities (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Total Current Liabilities data on file, last reported at $7.4 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.6 million, up 81.35% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.4 million, up from $5.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for EPRX reached as high as $19.4 million in Q4 2023 and fell as low as $2.4 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $7.0 million across 5 years, with a median of $4.7 million in 2025.
• Across the five-year window, Total Current Liabilities jumped 533.47% in 2023 and tumbled 83.98% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $3.1 million in 2022, then soared by 533.47% to $19.4 million in 2023, then tumbled by 83.98% to $3.1 million in 2024, then surged by 81.35% to $5.6 million in 2025, then surged by 30.82% to $7.4 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $7.4 million in Q1 2026, $5.6 million in Q4 2025, and $3.8 million in Q3 2025.